Yang Xie1, Meishu Xu1, Meihong Deng2, Zhigang Li2,3, Pengcheng Wang1, Songrong Ren1, Yan Guo1,4, Xiaochao Ma1, Jie Fan2,3, Timothy R Billiar2, Wen Xie1,5. 1. Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA. 2. Department of Surgery, University of Pittsburgh, Pittsburgh, PA. 3. Surgical Research, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA. 4. Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 5. Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA.
Abstract
Hemorrhagic shock (HS) is a life-threatening condition associated with tissue hypoperfusion and often leads to injury of multiple organs including the liver. Pregnane X receptor (PXR) is a species-specific xenobiotic receptor that regulates the expression of drug-metabolizing enzymes (DMEs) such as the cytochrome P450 (CYP) 3A. Many clinical drugs, including those often prescribed to trauma patients, are known to activate PXR and induce CYP3A. The goal of this study is to determine whether PXR plays a role in the regulation of DMEs in the setting of HS and whether activation of PXR is beneficial or detrimental to HS-induced hepatic injury. PXR transgenic, knockout, and humanized mice were subject to HS, and the liver injury was assessed histologically and biochemically. The expression and/or activity of PXR and CYP3A were manipulated genetically or pharmacologically in order to determine their effects on HS-induced liver injury. Our results showed that genetic or pharmacological activation of PXR sensitized wild-type and hPXR/CYP3A4 humanized mice to HS-induced hepatic injury, whereas knockout of PXR protected mice from HS-induced liver injury. Mechanistically, the sensitizing effect of PXR activation was accounted for by PXR-responsive induction of CYP3A and increased oxidative stress in the liver. The sensitizing effect of PXR was attenuated by ablation or pharmacological inhibition of CYP3A, treatment with the antioxidant N-acetylcysteine amide, or treatment with a PXR antagonist. Conclusion: We have uncovered a function of PXR in HS-induced hepatic injury. Our results suggest that the unavoidable use of PXR-activating drugs in trauma patients has the potential to exacerbate HS-induced hepatic injury, which can be mitigated by the coadministration of antioxidative agents, CYP3A inhibitors, or PXR antagonists.
Hemorrhagic shock (HS) is a life-threatening condition associated with tissue hypoperfusion and often leads to injury of multiple organs including the liver. Pregnane X receptor (PXR) is a species-specific xenobiotic receptor that regulates the expression of drug-metabolizing enzymes (DMEs) such as the cytochrome P450 (CYP) 3A. Many clinical drugs, including those often prescribed to traumapatients, are known to activate PXR and induce CYP3A. The goal of this study is to determine whether PXR plays a role in the regulation of DMEs in the setting of HS and whether activation of PXR is beneficial or detrimental to HS-induced hepatic injury. PXRtransgenic, knockout, and humanized mice were subject to HS, and the liver injury was assessed histologically and biochemically. The expression and/or activity of PXR and CYP3A were manipulated genetically or pharmacologically in order to determine their effects on HS-induced liver injury. Our results showed that genetic or pharmacological activation of PXR sensitized wild-type and hPXR/CYP3A4 humanized mice to HS-induced hepatic injury, whereas knockout of PXR protected mice from HS-induced liver injury. Mechanistically, the sensitizing effect of PXR activation was accounted for by PXR-responsive induction of CYP3A and increased oxidative stress in the liver. The sensitizing effect of PXR was attenuated by ablation or pharmacological inhibition of CYP3A, treatment with the antioxidant N-acetylcysteine amide, or treatment with a PXR antagonist. Conclusion: We have uncovered a function of PXR in HS-induced hepatic injury. Our results suggest that the unavoidable use of PXR-activating drugs in traumapatients has the potential to exacerbate HS-induced hepatic injury, which can be mitigated by the coadministration of antioxidative agents, CYP3A inhibitors, or PXR antagonists.
Authors: W Xie; J L Barwick; M Downes; B Blumberg; C M Simon; M C Nelson; B A Neuschwander-Tetri; E M Brunt; P S Guzelian; R M Evans Journal: Nature Date: 2000-07-27 Impact factor: 49.962
Authors: Haibiao Gong; Shivendra V Singh; Sharda P Singh; Ying Mu; Jung Hoon Lee; Simrat P S Saini; David Toma; Songrong Ren; Valerian E Kagan; Billy W Day; Piotr Zimniak; Wen Xie Journal: Mol Endocrinol Date: 2005-09-29
Authors: Hongwei Wang; Haiyan Huang; Hao Li; Denise G Teotico; Michael Sinz; Sharyn D Baker; Jeffrey Staudinger; Ganjam Kalpana; Matthew R Redinbo; Sridhar Mani Journal: Clin Cancer Res Date: 2007-04-15 Impact factor: 12.531
Authors: Antonius E van Herwaarden; Els Wagenaar; Cornelia M M van der Kruijssen; Robert A B van Waterschoot; Johan W Smit; Ji-Ying Song; Martin A van der Valk; Olaf van Tellingen; José W A van der Hoorn; Hilde Rosing; Jos H Beijnen; Alfred H Schinkel Journal: J Clin Invest Date: 2007-11 Impact factor: 14.808
Authors: Lauryn K Kohut; Sophie S Darwiche; John M Brumfield; Alicia M Frank; Timothy R Billiar Journal: J Vis Exp Date: 2011-06-06 Impact factor: 1.355
Authors: Yang Xie; Anne Caroline S Barbosa; Meishu Xu; Patrick J Oberly; Songrong Ren; Robert B Gibbs; Samuel M Poloyac; Wen-Chao Song; Jie Fan; Wen Xie Journal: Endocrinology Date: 2020-01-01 Impact factor: 4.736
Authors: Andrew D Huber; William C Wright; Wenwei Lin; Kinjal Majumder; Jonathan A Low; Jing Wu; Cameron D Buchman; David J Pintel; Taosheng Chen Journal: Cell Mol Life Sci Date: 2020-03-30 Impact factor: 9.261